KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
On Jul. 7, 2025, KalVista Pharmaceuticals announced that the U.S. Food and Drug Administration(FDA) has approved EKTERLY® (sebetralstat),…